Caris Life Sciences, Inc. (CAI) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Caris Life Sciences, Inc. $5.94, price $31.65, upside -81.2%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Caris Life Sciences, Inc. Common Stock for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
15‑month range $14.55 – $39.30 · fair‑value band $3.96 – $9.44 · the $31.65 price screens above the $5.94 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Caris Life Sciences, Inc. Common Stock in your weekly email
Every Wednesday you see whether Caris Life Sciences, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.
Show more
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
Stock analysis
Caris Life Sciences, Inc. Common Stock (CAI) currently trades at $31.65, while our model-based Fair Value estimate is $5.94, implying the stock looks roughly 432.8% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $7.04 per share, and 0 of the 13 models we run sit above the $31.65 price.
Bear case: the Asset-Based group reads lowest at $1.37, and 13 of the 13 models stay below the price. Evidence for this calculation is low.
Scenario range: $3.96 (bear) to $9.44 (bull), the price of $31.65 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Caris Life Sciences, Inc. Common Stock reported revenue of $812M in FY2025 versus $294M in FY2020, a compound +22.5%/yr. Reported net income was −$538M in FY2025.
Key figures
Market cap $5.2B · P/S ratio 5.75 · EPS (TTM) $−2.76 · Net margin −66.2% · Return on equity 28.4% · Return on assets (EBIT) −37.4% · Operating margin 2.4% · Revenue (TTM) $907M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 118% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −81%, CAI screens richer than that median.
Fair Value models
Bear $3.96Fair Value $5.94Bull $9.44
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.78/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+97.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+46.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.5%
Start year 2020 (pandemic). Over 10 years: +12.5% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
’13
’14
’15
’16
’17
’18
’19
’20
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
31.3% (2019) → −62.4% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+17.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +15.2% a year for the forecasts.
News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Compare Caris Life Sciences, Inc. Common Stock with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 5/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score47 · Above median
Fair Value upside−81% · Bottom 25%
Profitability
Return on equity (TTM)28% · Top 25%
Return on assets9% · Top 25%
Net margin (TTM)4% · Below median
Operating margin (TTM)2% · Above median
Growth and dividend
Revenue growth79% · Top 25%
Balance sheet
Debt / equity0.66× · Highest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)100· sector 0
HEALTH (low debt)67· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Caris Life Sciences, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/CAI
Frequently asked questions
Is Caris Life Sciences, Inc. (CAI) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $5.94 versus a price of $31.65, about −81% upside (overvalued).
What is the fair value of CAI?
Our model-based fair value for Caris Life Sciences, Inc. Common Stock is $5.94 (as of Sep 23, 2026), built from audited fundamentals. The current price: $31.65.
What is the quality score of CAI?
Caris Life Sciences, Inc. Common Stock has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Caris Life Sciences, Inc. (CAI)?
Our model-based price target is the fair value of $5.94 (as of Sep 23, 2026) from 13 valuation models. Cautious scenario $3.96, optimistic scenario $9.44. It is a calculation from audited fundamentals, not an analyst target.
What is the Caris Life Sciences, Inc. Common Stock stock forecast for 2026?
Our models put fair value at $5.94, about −81% upside versus a price of $31.65 (overvalued). Cautious scenario $3.96, optimistic scenario $9.44. The calculation is refreshed regularly with new filings.
What is the revenue of Caris Life Sciences, Inc. (CAI)?
Caris Life Sciences, Inc. Common Stock reported trailing-twelve-month revenue of about $907M (latest available figure, as of Sep 23, 2026).
What growth is priced into Caris Life Sciences, Inc. (CAI)?
For today's price to be fair in a discounted-cash-flow model, Caris Life Sciences, Inc. Common Stock would have to grow free cash flow by more than 80 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +22.5 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of CAI use?
Our models discount Caris Life Sciences, Inc. Common Stock at 9.7 %: a base by market capitalisation (mid), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Caris Life Sciences, Inc. Common Stock that is more than 80 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has Caris Life Sciences, Inc. (CAI) delivered so far?
Over the past 5 years revenue at Caris Life Sciences, Inc. Common Stock grew +22.5 % a year. The price currently implies more than 80 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Caris Life Sciences, Inc. (CAI) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Caris Life Sciences, Inc. Common Stock (more than 80 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Caris Life Sciences, Inc. (CAI)?
The free-cash-flow yield on the price is 0.13 %: that much free cash flow Caris Life Sciences, Inc. Common Stock produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Caris Life Sciences, Inc. (CAI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Caris Life Sciences, Inc. Common Stock it is $5.94 per share (as of Sep 23, 2026), against a price of $31.65. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Caris Life Sciences, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Sep 23, 2026, CAI trades above its calculated fair value: price $31.65, fair value $5.94, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CAI?
No. The price is what the market pays today ($31.65); the fair value is what the company's own numbers justify ($5.94). For Caris Life Sciences, Inc. Common Stock the two are $25.71 per share apart. That gap is exactly why we show both numbers side by side.
How much is Caris Life Sciences, Inc. Common Stock worth?
The market values Caris Life Sciences, Inc. Common Stock at about $5.2B (market capitalisation, as of Sep 23, 2026). Per share that is $31.65; our models calculate a fair value of $5.94 per share.
What do the bullish and bearish scenarios say about CAI?
Our models span a range for Caris Life Sciences, Inc. Common Stock: cautious scenario $3.96, base $5.94, optimistic $9.44 per share (as of Sep 23, 2026, price $31.65). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Caris Life Sciences, Inc. (CAI)?
Balance-sheet figures for Caris Life Sciences, Inc. Common Stock (as of Sep 23, 2026): return on equity 28.4%, debt of 0.66 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is CAI from its 52-week high?
Caris Life Sciences, Inc. Common Stock trades at $31.65, about 4% below its 52-week high of $32.95 and 118% above the low of $14.55 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $5.94 is for.
Which stocks are comparable to Caris Life Sciences, Inc. Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Caris Life Sciences, Inc. Common Stock stock attractive at the current price?
The data as of Sep 23, 2026: price $31.65, calculated fair value $5.94 (−81%), Quality Score 47/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CAI calculated?
We run Caris Life Sciences, Inc. Common Stock through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $5.94, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Caris Life Sciences, Inc. Common Stock itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Caris Life Sciences, Inc. (CAI)?
The closing price on Sep 23, 2026 was $31.65. Our model-based fair value is $5.94, about −81% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Caris Life Sciences, Inc. Common Stock right now?
The price sits above even our optimistic bull case ($9.44). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($3.96 to $9.44) leaves room in how you read the outcome.
Key figures of Caris Life Sciences, Inc. Common Stock
How large is the market capitalisation of Caris Life Sciences, Inc. (CAI)?
The market capitalisation of Caris Life Sciences, Inc. Common Stock is $5.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Caris Life Sciences, Inc. (CAI)?
The price-to-sales ratio of Caris Life Sciences, Inc. Common Stock is 5.75 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Caris Life Sciences, Inc. (CAI)?
Earnings per share at Caris Life Sciences, Inc. Common Stock are $−2.76. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Caris Life Sciences, Inc. (CAI)?
The net margin of Caris Life Sciences, Inc. Common Stock is −66.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Caris Life Sciences, Inc. (CAI)?
The return on equity (ROE) of Caris Life Sciences, Inc. Common Stock is 28.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Caris Life Sciences, Inc. (CAI)?
On an EBIT basis the return on assets of Caris Life Sciences, Inc. Common Stock is −37.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Caris Life Sciences, Inc. (CAI)?
The operating margin of Caris Life Sciences, Inc. Common Stock is 2.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Caris Life Sciences, Inc. (CAI)?
Revenue at Caris Life Sciences, Inc. Common Stock is growing +78.8% versus a year earlier (3y avg +46.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does Caris Life Sciences, Inc. (CAI) hold?
Caris Life Sciences, Inc. Common Stock holds more cash than debt, $419M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Caris Life Sciences, Inc. Common Stock in the live analysis
One click puts Caris Life Sciences, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026